The Central Drugs Standard Control Organisation (CDSCO) had set the October 1 deadline for bringing ‘class C and ‘class D medical devices under regulation as part of quality control efforts. To obtain the licences several manufacturers had submitted applications, but the government failed to provide them on time.
Primary Healthtech Pvt. Ltd., an alumni-led start-up from the Indian Institute of Technology (IIT) Guwahati, has developed a point-of-care-testing (POCT) device called MobilabTM. The device can test 25 parameters in blood to diagnose early chronic diseases related to kidney, liver, heart, and pancreas malfunctions. Operated through an IoT-enabled Android app, MobilabTM can perform about 150 tests with a single battery charge. The device aims to provide frugal, portable, affordable, and accessible diagnostics, especially in remote areas. It is expected to help in the early screening of non-communicable diseases and improve disease management at an affordable cost for millions of people.
India s Uttar Pradesh state has allowed Marion Biotech s factory, linked to cough syrups causing child deaths, to resume most production. The World Health Organization (WHO) had linked Marion s syrups to the deaths of 141 children in Uzbekistan, Gambia, and Cameroon. The state drug controller stated that there were no known quality issues with other medicines produced by Marion.
Private equity firms BPEA EQT and Ontario Teachers Pension Plan Board are considering acquiring Aster DM Healthcare Ltd. s assets in India. The deal would allow the investors to tap into the growth potential of healthcare services in the country. Other potential bidders for Aster s India business include Blackstone and KKR.
The law officer said the termination of pregnancy was recommended despite the medical board saying that the foetus had a viable chance of being born and "they would have to conduct a foeticide".